BPH/LUTS is prevalent in ~26% and ~46% of men aged 40–49 years and 70–79 years, respectively; impacting QoL.
EjD is prominent in men with LUTS, having decreased force of ejaculation in 77.9% and decreased semen in 74.4%.
But 70% of sexually active men Invariably discontinue BPH therapy if sex life is negatively impacted.
A systematic review of six studies comprising 1371 men evaluated the impact of alfuzosin on ejaculatory function while treating BPH/LUTS using two questionnaires: IPSS and MSHQ-EjD-SF.
Alfuzosin Sustains Long-Lasting LUTS Relief
Significantly reduced IPSS with a median decrease of 6.6 points, range: 2.5–9.3.
Most studies showed LUTS improvement within 6 months, with one study reporting results as early as 3 months.
Sustained IPSS improvement was observed over 2 years of alfuzosin treatment in one study.
Alfuzosin Improves Ejaculatory Function For Longer Duration
| Increased median MSHQ-EjD-SF scores by 1.9 points, range: 0.9–5.8, indicating improved ejaculatory function. |  |
 |
One study demonstrated a sustained improvement in MSHQ-EjD-SF scores over~2 years, with a mean increase of 5 points. |
Alfuzosin may improve ejaculatory function in addition to LUTS and should be considered in men who are sexually active or who already complain of deteriorating ejaculation.
Alfoo-Improved Pharmacokinetics
ALFOO, containing Alfuzosin molecule, is Anti-BPH which helps in treatment of LUTS due to BPH in Young Sexually Active Male in 40-60 year old age group
